Loading...
Market
What will be the Phase III trial results for CN201 by June 30, 2025?
2
Resolution / Starting Odds
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%
Official trial results published by Merck or clinical trial registries
Story
Merck Acquires CN201 B-Cell Therapy for Up to $1.3 Billion
Aug 9, 2024, 12:11 PM
Merck has announced its acquisition of CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical. CN201 is a next-generation CD3xCD19 bispecific antibody that aims to enhance and diversify Merck's pipeline. The drug has potential applications in treating B-cell malignancies and autoimmune diseases. The deal is valued at up to $1.3 billion, reflecting Merck's continued investment in innovative therapies.
View original story
Similar markets
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worsening condition • 25%
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Positive • 25%
Negative • 25%
Mixed • 25%
No Results • 25%
Successful with no major adverse effects • 25%
Successful with minor adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
Unsuccessful due to major adverse effects • 25%
Positive outcome with significant efficacy • 25%
Mixed outcome with limited efficacy • 25%
Negative outcome with no efficacy • 25%
Trial terminated early due to safety concerns • 25%
Phase II trial completion • 25%
Phase III trial commencement • 25%
FDA approval • 25%
None of the above • 25%
Primary endpoint met • 25%
Primary endpoint not met • 25%
Trial halted due to safety concerns • 25%
Other • 25%
Meets primary endpoint • 25%
Fails primary endpoint • 25%
Mixed results • 25%
Trial not completed by end of 2025 • 25%